Department of Haematology, Imperial College, Hammersmith Hospital, Ducane Road, London, UK.
Nat Rev Clin Oncol. 2010 Jun;7(6):303-4. doi: 10.1038/nrclinonc.2010.68.
Imatinib 400 mg has been the first-line therapy for chronic myeloid leukemia (CML) since 2001 but may have been licensed at too low a dose. A recent study compared the standard dose with higher doses in patients with newly diagnosed CML and found no difference in response rates at 12 months. But, is the devil in the detail?
自 2001 年以来，伊马替尼 400mg 一直是慢性髓性白血病（CML）的一线治疗药物，但剂量可能过低。最近的一项研究比较了新诊断的 CML 患者的标准剂量与较高剂量，发现 12 个月时的反应率没有差异。但是，细节决定成败吗？
